ATE358732T1 - Anti-virale vektoren - Google Patents

Anti-virale vektoren

Info

Publication number
ATE358732T1
ATE358732T1 AT99904956T AT99904956T ATE358732T1 AT E358732 T1 ATE358732 T1 AT E358732T1 AT 99904956 T AT99904956 T AT 99904956T AT 99904956 T AT99904956 T AT 99904956T AT E358732 T1 ATE358732 T1 AT E358732T1
Authority
AT
Austria
Prior art keywords
viral
nucleotide sequence
encoding
assembly
particles
Prior art date
Application number
AT99904956T
Other languages
English (en)
Inventor
Alan John Greystones Kingsman
Kyriacos Mitrophanous
Narry Kim
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10827139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE358732(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE358732T1 publication Critical patent/ATE358732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99904956T 1998-02-17 1999-02-17 Anti-virale vektoren ATE358732T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9803351.7A GB9803351D0 (en) 1998-02-17 1998-02-17 Anti-viral vectors

Publications (1)

Publication Number Publication Date
ATE358732T1 true ATE358732T1 (de) 2007-04-15

Family

ID=10827139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99904956T ATE358732T1 (de) 1998-02-17 1999-02-17 Anti-virale vektoren

Country Status (10)

Country Link
US (2) US6541248B1 (de)
EP (2) EP1054988B1 (de)
JP (1) JP2002503477A (de)
CN (1) CN1297486A (de)
AT (1) ATE358732T1 (de)
AU (1) AU757284B2 (de)
CA (1) CA2321097A1 (de)
DE (1) DE69935714T2 (de)
GB (1) GB9803351D0 (de)
WO (1) WO1999041397A1 (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1980617A1 (de) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1535995A1 (de) * 1998-12-31 2005-06-01 Chiron Corporation Polynukleotide kodierend für Antigene des HIV Type C ENV Polypeptids, und Verwendungen davon
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
EP1240333B1 (de) 1999-11-16 2008-04-09 Geneart Ag Das genom des hiv-1 intersubtyps (c/b') und seine anwendungen
WO2001068836A2 (en) * 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
DE60045932D1 (de) * 2000-09-01 2011-06-16 Gen Probe Inc HIV-1-Sequenzverstärkung zur Erkennung von Sequenzen in Zusammenhang mit Wirkstoffresistenz-Mutationen
AU2001294562B2 (en) * 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
CZ2003784A3 (cs) * 2000-09-22 2003-11-12 Virxsys Corporation Zlepšené podmíněně se replikující vektory, způsoby jejich produkce a jejich použití
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
CA2441209C (en) 2001-01-25 2012-11-13 Virxsys Corporation Methods and compositions for identifying gene function
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
DK1504108T3 (da) * 2002-02-01 2013-06-10 Oxford Biomedica Ltd Lentivirusvektor
GB0526211D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
EP3293266B1 (de) 2007-05-04 2025-12-24 University Health Network Il-12-immuntherapie gegen krebs
US20090088625A1 (en) * 2007-10-01 2009-04-02 Kenneth Oosting Photonic Based Non-Invasive Surgery System That Includes Automated Cell Control and Eradication Via Pre-Calculated Feed-Forward Control Plus Image Feedback Control For Targeted Energy Delivery
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
WO2012075337A2 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
US10106816B2 (en) * 2012-12-14 2018-10-23 Case Western Reserve University Genomic RNA packaging enhancer element
EP2986635B1 (de) 2013-04-18 2018-10-03 Fondazione Telethon Effektive übertragung von grosen genen durch dual-aav-vektoren
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
MX378859B (es) 2014-09-15 2025-03-11 Molmed Spa Receptores de antigenos quimericos.
GB201418965D0 (de) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
WO2016100389A1 (en) 2014-12-16 2016-06-23 Synthetic Genomics, Inc. Compositions of and methods for in vitro viral genome engineering
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
ES2987957T3 (es) 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
US20190017096A1 (en) 2016-03-10 2019-01-17 Nightstarx Limited Prenylation assay
EP3318285A1 (de) 2016-11-08 2018-05-09 Oxford University Innovation Limited Behandlung von augenerkrankungen
CN109952377A (zh) 2016-12-01 2019-06-28 雀巢产品技术援助有限公司 调节fam46a的方法
EP3375876A1 (de) 2017-03-13 2018-09-19 Evonetix Ltd Verfahren zur herstellung von dobbeltsträngigen polynukleotiden basierend auf oligonukleotiden mit ausgewählten und unterschiedlichen schmelztemperaturen
EP3601566A1 (de) 2017-03-31 2020-02-05 Société des Produits Nestlé S.A. Verfahren zur modulation von ank1
EP4491233A3 (de) * 2017-04-21 2025-04-16 Ospedale San Raffaele S.r.l. Gentherapie
IL270084B2 (en) 2017-04-24 2026-03-01 Ospedale San Raffaele Srl TCR binding peptide from WILMS TUMOUR 1 protein and its use in cancer therapy
WO2019068854A1 (en) 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
EP3697923A1 (de) 2017-10-17 2020-08-26 Nightstarx Limited Prenylierungstest
JP7477448B2 (ja) 2017-11-21 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｌｋを調節する方法
EP3696272A1 (de) 2017-12-22 2020-08-19 Oxford BioMedica (UK) Limited Retroviraler vektor
WO2019134866A1 (en) 2018-01-03 2019-07-11 Molmed Spa Chimeric antigen receptors containing optimal spacer region
CN112004924A (zh) 2018-04-18 2020-11-27 Ucl商务有限公司 增强treg细胞抑制特性的方法
MX2020012295A (es) 2018-05-15 2021-03-31 Flagship Pioneering Innovations V Inc Composiciones de fusosoma y usos de estas.
WO2019219308A1 (en) 2018-05-17 2019-11-21 Societe Des Produits Nestle S.A. Methods of modulating nkx6.3
KR20210016567A (ko) 2018-05-30 2021-02-16 글리코스템 떼라퓨틱스 비.브이. Car nk 세포
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
GB201817821D0 (en) 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
WO2020102485A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
AU2019400930A1 (en) 2018-12-19 2021-07-01 King's College London Immunotherapeutic methods and compositions
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
CA3133188A1 (en) 2019-03-10 2020-09-17 Oxford Biomedica (Uk) Limited Gene therapy compositions and methods for treating parkinson's disease
GB201905301D0 (en) 2019-04-15 2019-05-29 Ospedale San Raffaele Srl Gene therapy
GB201907493D0 (en) 2019-05-28 2019-07-10 Ospedale San Raffaele Agents and methods for treating viral infections
GB201912515D0 (en) 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
KR20220097492A (ko) 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
JP2023513303A (ja) 2020-02-13 2023-03-30 オックスフォード バイオメディカ（ユーケー）リミテッド レンチウイルスベクターの製造
US20230138428A1 (en) 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20230118587A1 (en) 2020-03-13 2023-04-20 Oxford Biomedica (Uk) Limited Lentiviral Vectors
EP4127144A1 (de) 2020-03-31 2023-02-08 Sana Biotechnology, Inc. Zielgerichtete lipidpartikel und zusammensetzungen und verwendungen davon
WO2021222222A1 (en) 2020-04-27 2021-11-04 Mccray Jr Paul B Compositions and methods for the treatment of cystic fibrosis
GB202007169D0 (en) 2020-05-14 2020-07-01 Ospedale San Raffaele Srl Epidermal growth factor receptor
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
GB202018657D0 (en) 2020-11-26 2021-01-13 Ospedale San Raffaele Srl Agents and methods for increasing liver immune response
WO2022136874A1 (en) 2020-12-23 2022-06-30 Quell Therapeutics Limited Inducible signalling protein
CA3204161A1 (en) 2021-01-11 2022-07-14 Jagesh Vijaykumar SHAH Use of cd8-targeted viral vectors
CA3207166A1 (en) 2021-02-01 2022-08-04 Angelo Leone Lombardo Gene silencing
US20240101623A1 (en) 2021-02-15 2024-03-28 Ospedale San Raffaele S.R.L. Epigenetic silencing for treatment of cancer
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
CN117377771A (zh) 2021-05-12 2024-01-09 特莱索恩基金会 载体系统
WO2022251712A1 (en) 2021-05-28 2022-12-01 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
US20240344083A1 (en) 2021-08-04 2024-10-17 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023047098A2 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-p75ntr chimeric antigen receptor
US20240390422A1 (en) 2021-09-21 2024-11-28 Quell Therapeutics Limited Anti-trem2 chimeric antigen receptor
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
US20250000966A1 (en) * 2021-10-13 2025-01-02 The Cleveland Clinic Foundation Mrna vaccine design via the alteration of codon usage
US20250230511A1 (en) 2021-10-29 2025-07-17 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
GB202117298D0 (en) 2021-11-30 2022-01-12 Quell Therapeutics Ltd Signalling protein
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023118878A1 (en) 2021-12-22 2023-06-29 Quell Therapeutics Limited Constitutive cytokine receptors
EP4209511A1 (de) 2022-01-05 2023-07-12 Gyala Therapeutics Sociedad Limitada Anti-cd84-antikörper amd chimäre antigenrezeptoren
AU2023205629A1 (en) 2022-01-05 2024-08-15 Fundació De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer Anti-cd84 antibodies and chimeric antigen receptors
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (de) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Auf cd3 abzielende lentivirale vektoren und verwendungen davon
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4269426A1 (de) 2022-04-29 2023-11-01 Ospedale San Raffaele S.r.l. Gentherapie
US20260000790A1 (en) 2022-07-08 2026-01-01 Ospedale San Raffaele S.R.L. Transgene cassettes
EP4303226A1 (de) 2022-07-08 2024-01-10 Ospedale San Raffaele S.r.l. Transgen-kassetten und epigenetische schalldämpfer zur behandlung von störungen
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024033544A1 (en) 2022-08-12 2024-02-15 Ospedale San Raffaele S.R.L. Deglycosylation of native glycoproteins expressed on a tumor cell surface
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024100145A1 (en) 2022-11-08 2024-05-16 Ospedale San Raffaele S.R.L. Polynucleotide and vector
CN120882745A (zh) 2022-11-11 2025-10-31 圣拉斐尔医院有限责任公司 Cdh17 car
GB202217541D0 (en) 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
EP4651887A1 (de) 2023-01-16 2025-11-26 Ospedale San Raffaele S.r.l. T-zell-rezeptoren
EP4403580A1 (de) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimärer antigenrezeptor
TW202436337A (zh) 2023-01-23 2024-09-16 漢諾威醫學院 嵌合抗原受體
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (de) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimärer antigenrezeptor
EP4669343A1 (de) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover Chimärer antigenrezeptor
WO2024194223A2 (en) 2023-03-17 2024-09-26 Ospedale San Raffaele S.R.L. Gene therapy
EP4680728A1 (de) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg-therapie
EP4434539A1 (de) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimärer antigenrezeptor
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
CN121219020A (zh) 2023-03-22 2025-12-26 圣拉斐尔医院有限责任公司 基因疗法
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
GB202307366D0 (en) 2023-05-17 2023-06-28 Ospedale San Raffaele Srl Vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2024261480A1 (en) 2023-06-21 2024-12-26 Quell Therapeutics Limited Constitutive cytokine receptors
AU2024305679A1 (en) 2023-06-28 2026-01-22 Ospedale San Raffaele S.R.L. T-cell receptors
WO2025032194A1 (en) 2023-08-08 2025-02-13 Ospedale San Raffaele S.R.L. T-cell receptors
GB202316264D0 (en) 2023-10-24 2023-12-06 Ospendale San Raffaele S R L Gene therapy
IT202300022191A1 (it) 2023-10-24 2025-04-24 Fond Telethon Ets Mezzi e metodi per la modifica genetica di uba1
WO2025109189A1 (en) 2023-11-24 2025-05-30 Ospedale San Raffaele S.R.L. Engineered regulatory t cells and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
EP4640830A1 (de) 2024-04-23 2025-10-29 Fondazione Telethon ETS Mittel und verfahren zur sicheren und effizienten geneditierung in zellen
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
WO2026027876A1 (en) 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method
GB202415025D0 (en) 2024-10-11 2024-11-27 Ospedale San Raffaele Srl Cell
WO2026088097A1 (en) 2024-10-24 2026-04-30 Fondazione Telethon Ets Mutation-independent genome editing

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368882A1 (de) 1987-07-29 1990-05-23 BASF Lacke + Farben AG Kathodisch abscheidbare kunstharze enthaltende wässrige elektrotauchlackbäder und verfahren zur beschichtung elektrisch leitfähiger substrate
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996037781A1 (en) * 1995-05-26 1996-11-28 Asahi Kasei Kogyo Kabushiki Kaisha Method for assaying antibody inhibiting reverse transcriptase activity
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
NZ324157A (en) * 1995-11-28 2000-10-27 Univ Johns Hopkins Med Conditionally replicating viral vectors and their use in treating HIV
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
NZ326429A (en) 1996-01-23 2001-07-27 Oxford Biomedica Ltd A producer cell containing a DNA sequence lacks functional env and functional gag-pol genes capable of producing a retroviral vector containing neither and its use in gene therapy
ATE309366T1 (de) 1996-02-22 2005-11-15 Merck & Co Inc Synthetische hiv-gene
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB2325003B (en) 1996-10-17 2000-05-10 Oxford Biomedica Ltd Rectroviral vectors
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
CA2280195A1 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
EP0981636B1 (de) * 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Auf lentivirus basierende gentransfer-vektoren
ATE528405T1 (de) 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
AU6139699A (en) 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
US6958226B1 (en) * 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
HUP0201019A2 (en) 1999-04-26 2002-08-28 Leuven K U Res & Dev Synthetic gene for expressing active retroviral protein in eukaryotes
GB9923558D0 (en) 1999-10-05 1999-12-08 Oxford Biomedica Ltd Producer cell

Also Published As

Publication number Publication date
EP1790658A3 (de) 2007-09-12
EP1054988A1 (de) 2000-11-29
DE69935714T2 (de) 2007-12-27
AU2527499A (en) 1999-08-30
EP1054988B1 (de) 2007-04-04
EP1790658A2 (de) 2007-05-30
DE69935714D1 (de) 2007-05-16
AU757284B2 (en) 2003-02-13
US20040009603A1 (en) 2004-01-15
CN1297486A (zh) 2001-05-30
GB9803351D0 (en) 1998-04-15
CA2321097A1 (en) 1999-08-19
WO1999041397A1 (en) 1999-08-19
US6541248B1 (en) 2003-04-01
JP2002503477A (ja) 2002-02-05
US7790419B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
DE69935714D1 (de) Anti-virale vektoren
GB2363794A (en) Anti-viral vectors
ATE330007T1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
DK1895010T3 (da) Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
DE69638196D1 (de) Rekombinantes sendai-virus
DE69833652D1 (de) System zum exprimieren einer hyperthermostabilen protease
NZ319786A (en) HCV NS3 protein fragments with helicase activity and improved solubility
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
DK0842279T3 (da) Hjælpevirus til fremstilling af rekombinante virusvektorer
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
DE60237791D1 (de) Zytokinproteinfamilie
NZ527971A (en) Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
AU6839898A (en) Vaccine composition for preventing or treating c hepatitis
DE69230984D1 (de) Verwendung einer Herpesprotease
DE59109072D1 (de) Klonierung der N-Methylhydantoinase
WO1999057284A3 (en) Attenuated influenza viruses
DK0627004T3 (da) Forbedringer ved eller i forbindelse med malariavaccine
WO2001059108A3 (en) Inhibitors of apoptosis
IL136496A0 (en) Nucleotide sequences encoding the tomato light hypersensitive phenotype, encoded proteins and uses thereof
AU2002349094A1 (en) Hdv nucleic acid molecules, fragments and applications thereof
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
MX9606653A (es) Endopeptidasa de prolilo estable al calor.
ATE180015T1 (de) N-carbamoylsarcosin-amidohydrolase, kloniert

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties